Ensysce Biosciences Inc Asset Resilience Ratio
Ensysce Biosciences Inc asset resilience ratio. Ensysce Biosciences Inc (ENSC) has an Asset Resilience Ratio of 57.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ensysce Biosciences Inc (ENSC) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ensysce Biosciences Inc (2017–2022)
Asset resilience ratio of Ensysce Biosciences Inc from 2017 to 2022. This chart shows how Ensysce Biosciences Inc's Asset Resilience Ratio has changed over time. Read ENSC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ensysce Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Ensysce Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $4.31 Million | 57.84% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $4.31 Million | 57.84% |
Asset Resilience Insights
- Very High Liquidity: Ensysce Biosciences Inc maintains exceptional liquid asset reserves at 57.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ensysce Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Ensysce Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Ensysce Biosciences Inc Asset Resilience Ratio by Year (2017–2022)
Ensysce Biosciences Inc asset resilience ratio by year from 2017 to 2022. The table below shows the annual Asset Resilience Ratio data for Ensysce Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 53.49% | $3.15 Million | $5.89 Million | -21.22pp |
| 2021-12-31 | 74.71% | $12.26 Million | $16.42 Million | -24.68pp |
| 2019-12-31 | 99.39% | $195.31 Million | $196.51 Million | +0.32pp |
| 2018-12-31 | 99.06% | $202.92 Million | $204.83 Million | +0.20pp |
| 2017-12-31 | 98.86% | $200.12 Million | $202.43 Million | -- |
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more